Accessibility Menu
Alphatec logo

Alphatec(NASDAQ) ATEC

Market Cap$1.51BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2006)-91%
5 Year-21%
1 Year-38%
1 Month+18%
$9.73
+2.05%
+0.19Today
After hours$9.75+$0.02 (+0.26%)
Alphatec last closing stock price
MetricPriceDate
Last closeUSD 9.752026-08-19
Alphatec stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+1.25%USD 9.632026-08-12
1 month+17.9%USD 8.272026-07-20
3 month+18.47%USD 8.232026-05-21
Year to date-53.66%USD 21.042025-12-31
1 year-38.29%USD 15.802025-08-19
3 year-32.34%USD 14.412023-08-18
5 year-21.05%USD 12.352021-08-20
Since inception-90.95%USD 107.762006-06-02

Alphatec Financials at a Glance

Market Cap

$1.51BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$815.05M

Net Income (TTM)

-$109.99M

EPS (TTM)

-$0.72

P/E Ratio

-13.61

Dividend

$0.00

Beta (Volatility)

1.22 (Average)

Price

$9.73

Volume

3,154

Open

$9.53

Previous Close

$9.75

Daily Range

$9.50 - $10.00

52-Week Range

$6.82 - $23.29

Estimated Earnings Date

Oct 29, 2026

About Alphatec

Alphatec Holdings, Inc. helps surgeons treat complex spine disorders. Its technology lets doctors see nerves during operations. These tools help patients recover from back conditions.

Solving Spine Surgery Challenges

  • Alpha InformatiX Platform: Software systems designed to reduce nerve injury risks during spine procedures.
  • Spinal Fixation Systems: Hardware like screws and plates used to stabilize the spine.
  • Interbody Implants: Devices that help bones fuse together following surgical treatment.
  • Biologics Portfolio: Tissue-based materials and bone grafts that assist in the healing process.
  • EOS Imaging: Full-body X-ray equipment used for planning and assessing surgical outcomes.

Strategic Moves and Financing

  • Entered into a senior secured credit agreement with JP Morgan Chase Bank in May 2026.
  • Borrowed $175.0 million under a new term loan to restructure existing corporate debt in May 2026.
  • Expanded the strategic distribution channel through the addition of exclusive sales team members.
  • Increased product volume through a growing base of participating surgeons and hospitals.

What Makes Alphatec Different?

Alphatec integrates neural monitoring and imaging into procedural approaches to improve surgical predictability. The company focuses entirely on the spine market to create specialized solutions for complex pathologies.

Performance by the Numbers

  • Total revenue was $213.5 million for the three months ended June 30, 2026, up 15% year over year.
  • Revenue hit $405.6 million for the six-month period ended June 30, 2026, up 14% year over year.
  • Market capitalization was $1.3 billion in the second quarter of 2026, down 19.3% year over year.
  • Net cash provided by operating activities was $21.8 million for the six months ended June 30, 2026.
  • Cash and cash equivalents were $118.7 million as of June 30, 2026.

Bottom Line

Alphatec has transitioned into a provider of integrated surgical systems through its focus on clinical distinction. Its expansion into imaging and informatics marks a move beyond traditional spinal implants.

AI Generated • Aug 5, 2026

Industry

Healthcare Equipment and Supplies

Employees

913

CEO

Patrick S. Miles

Headquarters

Carlsbad, CA 92008, US

ATEC Financials

Key Financial Metrics (TTM)

Gross Margin

66.15%

Operating Margin

-5.55%

Net Income Margin

-13.50%

Return on Equity

-818.99%

Return on Capital

-12.52%

Return on Assets

-13.91%

Earnings Yield

-7.35%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.51BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

154.45M

Volume

3.15K

Avg. Volume

2.63M

Financials (TTM)

Gross Profit

$539.13M

Operating Income

-$45.26M

EBITDA

$13.46M

Operating Cash Flow

$56.53M

Capital Expenditure

-$52.37M

Free Cash Flow

$4.16M

Cash & ST Invst.

$118.66M

Total Debt

$604.02M

Alphatec Performance Analysis

Alphatec annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 350,867,00044.3%
20232023-12-31USD 482,262,00037.4%
20242024-12-31USD 611,562,00026.8%
20252025-12-31USD 764,155,00025.0%
Alphatec sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-305.9%
Q42025-12-318.4%
Q12026-03-31-9.8%
Q22026-06-3011.1%
Alphatec annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.46-2.4%
20232023-12-31USD -1.545.2%
20242024-12-31USD -1.13-26.3%
20252025-12-31USD -0.96-15.8%
Alphatec sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3029.6%
Q42025-12-3121.1%
Q12026-03-31-46.7%
Q22026-06-3027.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$213.51M

+15.1%

Gross Profit

$154.10M

+19.4%

Gross Margin

72.17%

N/A

Market Cap

$1.51BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.65M

N/A

Employees

913

N/A

Net Income

-$25.78M

+37.3%

EBITDA

$6.46M

+177.4%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$118.66M

-24.4%

Total Debt

$604.02M

+3.0%

Accounts Receivable

$110.13M

+10.3%

Inventory

$194.89M

+14.8%

Long Term Debt

$532.41M

-7.9%

Short Term Debt

$71.61M

+749.1%

Return on Assets

-13.91%

N/A

Return on Invested Capital

-8.18%

N/A

Free Cash Flow

$582.00K

-82.8%

Operating Cash Flow

$20.51M

+31.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SGRYSurgery Partners, Inc.
$13.60-4.49%
ZLABZai Lab Limited
$26.72+4.50%
IRONDisc Medicine, Inc.
$80.32+0.15%
IDYAIDEAYA Biosciences, Inc.
$38.87+2.48%

Trending Stocks

Symbol / CompanyPricePrice Chg
WBSWebster Financial
$77.57-0.01%
IBITiShares Bitcoin Trust
$38.78+0.06%
MRNAModerna
$174.38+1.77%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$120.74-0.06%

Questions About ATEC

What is the current price of Alphatec?

Alphatec is trading at $9.75 per share.

What is the 52-week range for Alphatec?

Over the past 52 weeks, Alphatec has traded between $6.82 and $23.29.

How much debt does Alphatec have?

As of the most recent reporting period, Alphatec reported total debt of $604.02M.

How much cash does Alphatec have on hand?

Alphatec reported $118.66M in cash and cash equivalents in its most recent financial results.

What is Alphatec’s dividend yield?

Alphatec does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.